UnknownPhase 3NCT01619046
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Green Cross Corporation
- Principal Investigator
- Paul LeoFrancis Giangrande, MDOxford Haemophilic Centre and Thrombosis Unit, Churchill Hospital
- Intervention
- GreenGene™ F and an approved recombinant Factor VIII product(biological)
- Enrollment
- 124 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2013 – 2015
Study locations (30)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Los Angeles Orthopaedic Hospital - Hemophilia Treatment Center, Los Angeles, California, United States
- Harbor - UCLA Pediatrics, Torrance, California, United States
- University of Miami - Comprehensive Hemophilia Center, Miami, Florida, United States
- St. Luke's Boise Medical Center, Boise, Idaho, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Michigan State University Center for Bleeding Disorders & Clotting Disorders, East Lansing, Michigan, United States
- Children's Mercy Hospital - Kansas City Regional Hemophilia Center, Kansas City, Missouri, United States
- Long Island Jewish Medical Center - Hemophilia Treatment Center, New Hyde Park, New York, United States
- Oregon Health and Science University, Portland, Oregon, United States
- University of Alberta, Edmonton, Alberta, Canada
- McMaster Children's Hospital, Hamilton, Ontario, Canada
- Research Associates, Ltd., Christchurch, New Zealand, New Zealand
- Instytut Hematologii i Transfuzjologii, Warsaw, Poland
- wojewodzki szpital Specjalistyczny, klinika hematologii uniwersytetu medycznego w łodzi, Łodzi, Poland
- +15 more locations on ClinicalTrials.gov
Collaborators
Atlantic Research Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01619046 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07416604A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia AHoffmann-La Roche
- RECRUITINGPHASE3NCT07545395Safety of KN057 Prophylaxis in Patients With Haemophilia A or BSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06992076Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience RegistryInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France